Lantern Pharma Inc. (LTRN) - 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Lantern Pharma Inc.
Reporting Period: Fiscal year ended December 31, 2025.
Business Model: An AI-focused biopharmaceutical company developing oncology therapies. The company utilizes its proprietary RADR® AI platform (containing over 200 billion data points) to identify, rescue, and develop small molecule drug candidates and antibody-drug conjugates (ADCs). The strategy involves targeting specific patient populations using biomarker-driven approaches to reduce development time and cost.
Key Assets: Three clinical-stage drug candidates (LP-300, LP-184, LP-284), an ADC program, and the RADR® AI platform. A wholly-owned subsidiary, Starlight Therapeutics, focuses on CNS/brain cancer indications for LP-184 (STAR-001).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(17,119,438) | $(20,781,213) |
| Operating Expenses | $17,978,494 | $22,216,437 |
| Research & Development (R&D) | $11,514,123 | $16,125,690 |
| General & Administrative (G&A) | $6,464,371 | $6,090,747 |
| Cash and Cash Equivalents (Year End) | $4,422,838 | $7,511,079 |
| Marketable Securities (Year End) | $5,696,386 | $16,501,984 |
| Total Liquidity (Cash + Securities) | $10,119,224 | $24,013,063 |
| Working Capital | $6,301,585 | $20,916,454 |
| Debt | $0 | $0 |
Note: The company has no long-term debt. Liquidity is derived from cash, cash equivalents, and marketable securities.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $3.66 million (17.6%) year-over-year, primarily due to a significant reduction in R&D expenses.
- R&D Expense Decline: R&D expenses dropped by approximately $4.61 million (29%), driven by decreases in research studies and materials ($4.03M), payroll ($0.61M), and consulting fees ($0.08M). This was partially offset by a $0.11M increase in licensing expenses.
- Liquidity Position: Total liquidity (cash and marketable securities) decreased significantly from ~$24.0 million in 2024 to ~$10.1 million in 2025. This reflects a net decrease in cash and cash equivalents of $3.09 million, driven by operating cash outflows of $15.68 million, partially offset by net redemptions of marketable securities ($11.06 million) and financing proceeds ($1.50 million).
- Financing Activity: In 2025, the company entered an "At-The-Market" (ATM) Sales Agreement and sold 356,922 shares for gross proceeds of $1.62 million. No such equity raises occurred in 2024.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: The independent auditor has expressed substantial doubt about the company's ability to continue as a going concern. Management estimates current resources will fund operations only until late July to mid-September 2026. Substantial additional funding is required to continue clinical trials and operations.
- Clinical Progress:
- LP-300: Advancing in the Phase 2 HARMONIC® trial for never-smokers with NSCLC. Enrollment expanded to Japan and Taiwan. A Type C meeting with the FDA is scheduled for May 2026 to discuss protocol amendments.
- LP-184 (STAR-001): Phase 1a enrollment completed. Future Phase 1b/2 trials planned for Triple Negative Breast Cancer (TNBC) and NSCLC. Received Fast Track Designation for Glioblastoma (GBM) and TNBC.
- LP-284: Phase 1a trial ongoing. Achieved a first complete metabolic response in a heavily pre-treated DLBCL patient.
- Strategic Initiatives: Introduced "withZeta.ai," a generative AI platform for rare cancer research, in January 2026. Plans to commercialize AI platforms as a revenue source in 2026.
- Risks:
- Funding: High risk of inability to raise capital, which could force delays or elimination of drug programs.
- Regulatory: No drug candidates have received marketing approval. Success depends on clinical trial outcomes and FDA/EMA approvals.
- Competition: Intense competition from major pharma and AI-focused biotech firms.
- Intellectual Property: Reliance on in-licensed patents with varying expiration dates; some core compounds (LP-300) lack composition of matter patent protection.
Key Facts for Investor Verification
- Cash Runway: Verify the company's ability to secure funding before late July 2026 to avoid operational disruption.
- LP-300 Trial Amendments: Monitor the outcome of the FDA Type C meeting in May 2026 regarding the HARMONIC® trial design changes (single-arm conversion, EGFR mutation focus).
- LP-184/STAR-001 Biomarkers: Confirm the validation of the PTGR1 biomarker and the initiation of planned Phase 1b/2 trials in TNBC and NSCLC.
- AI Commercialization: Assess the progress of the "withZeta.ai" platform and any potential revenue generation from AI licensing or services in 2026.
- Stock Dilution: Monitor future equity issuances under the ATM facility or new capital raises, which will likely dilute existing shareholders.